Diet, Metabolism, and Disease / Liver Disease Diagnosis and Treatment · Journal article

Metabolic Dysfunction-Associated Steatotic Liver Disease: A Dark Horse of Metabolic Syndrome

Journal of Medicine · September 6, 2026

Expert Guidance Why this matters to you Expert discussion

A consensus or society position rather than new primary data.

AI Summary

This is a narrative review that reframes non-alcoholic fatty liver disease (NAFLD) as metabolic dysfunction-associated steatotic liver disease (MASLD), emphasizing the requirement for at least one cardiometabolic risk factor in diagnosis. The paper synthesizes pathogenic pathways (insulin resistance, adipose tissue dysfunction, de novo lipogenesis) and clinical associations with cardiovascular disease, chronic kidney disease, and malignancy, but provides no new empirical findings or outcome data to support clinical decision-making.

What was studied

Journal article. Patients with metabolic dysfunction-associated steatotic liver disease and metabolic syndrome.

Key findings

MASLD nomenclature now requires at least one of four defined cardiometabolic risk factors, differing from prior NAFLD terminology Insulin resistance is nearly universal in MASLD and operates across liver, adipose tissue, and muscle MASLD is associated with increased risk of cardiovascular events, chronic kidney disease, hepatic and extrahepatic malignancies, and liver-related outcomes including liver failure

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

Clinicians should recognize MASLD as a systemic manifestation of metabolic dysfunction rather than isolated liver disease, warranting integrated cardio-metabolic assessment and management. This conceptual reframing supports a holistic approach to risk stratification and prevention of cardiovascular and renal complications.

Plain-language summary

A narrative review synthesizing pathogenic mechanisms and clinical relationships of MASLD with metabolic syndrome, offering conceptual framework rather than new empirical evidence.

Clinical bottom line

Caveats

No quantitative estimates of incidence, prevalence, or risk magnitude are provided
No systematic review methodology or evidence synthesis is reported
No original outcome data, trial results, or comparative effectiveness data are presented
The paper does not cite specific studies or provide a formal literature appraisal

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Narrative review; no primary research design or data collection described.

Directness

moderate

Addresses MASLD pathogenesis and clinical associations but does not present outcome data or intervention trials.

Consistency

insufficient

No comparison of multiple studies or assessment of agreement across sources reported.

Risk of bias

insufficient

Review article; no systematic appraisal of bias in included studies or methodology disclosed.

Sample adequacy

insufficient

No original data collection; narrative synthesis only.

What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely related to obesity, type 2 diabetes mellitus, hypertension, and other cardiometabolic risk factors, with an increased risk of cardiovascular events, chronic kidney disease, hepatic and extrahepatic malignancies, and also liver-related outcomes, including liver failure. The nomenclature MASLD has a long evolution history from 1836 to 2023. The term Non Alcoholic Fatty Liver Disease (NAFLD) used previously did not include cardio-metabolic risk factors as diagnostic criteria. By contrast, MASLD should have at least one of the four defined cardiometabolic risk factors. Insulin resistance is nearly universal in patients with MASLD and is present in the liver, adipose tissue, and muscle. Adipose tissue insulin resistance is characterized by increased release of free fatty acids (FFA) from adipocytes (lipolysis) in the fasting state, which accumulate inside the liver and undergo triglyceride formation. Dietary carbohydrates, in the form of dietary sugars (e.g., fructose, sucrose, and glucose), drive the formation and accumulation of intrahepatic fat from de novo lipogenesis (DNL). This review discusses in depth the pathogenesis of hepatic steatosis and inflammation that may lead to hepatic cellular damage, fibrosis, and cirrhosis. The relationship of MASLD with type-2 diabetes mellitus, hypertension, obesity, and lipid abnormalities is also discussed in detail. In fact, MASLD should be viewed as a hepatic manifestation of metabolic syndrome. There are numerous mechanisms that may accelerate atherosclerosis and premature cardiovascular disease (CVD) in patients with MASLD. So MASLD should not be considered as an isolated disease; rather, it should be viewed as part of a spectrum of disease conditions. Its connectivity with other cardio-metabolic conditions highlights the importance of this dark horse of metabolic disorders. J MEDICINE 2026; 27(2): 128-135

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Muhammad HezbullahDiet, Metabolism, and DiseaseLiver Disease Diagnosis and TreatmentSharifa SultanaMohammad Abdullah